Holen Sie sich die Stockscreener-App
46.74
1.30%
0.56
Schlusskurs vom Vortag:
$46.18
Offen:
$47.08
24-Stunden-Volumen:
3.62M
Relative Volume:
0.66
Marktkapitalisierung:
$8.38B
Einnahmen:
$1.36B
Nettoeinkommen (Verlust:
$-302.91M
KGV:
-27.20
EPS:
-1.7182
Netto-Cashflow:
$-219.93M
1W Leistung:
+2.75%
1M Leistung:
-10.25%
6M Leistung:
-39.41%
1J Leistung:
-25.22%
1-Tages-Spanne:
$46.22
$48.21
1-Wochen-Bereich:
$44.30
$48.21
52-Wochen-Spanne:
$41.73
$104.32
Tempus Ai Inc Stock (TEM) Company Profile
Firmenname
Tempus Ai Inc
Sektor
Branche
Telefon
800-976-5448
Adresse
600 WEST CHICAGO AVENUE, CHICAGO
Compare TEM vs VEEV, BTSG, HQY, HNGE
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TEM
Tempus Ai Inc
|
46.69 | 8.29B | 1.36B | -302.91M | -219.93M | -1.7182 |
VEEV
Veeva Systems Inc
|
158.00 | 26.14B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
60.19 | 11.34B | 13.65B | 169.86M | 412.12M | 1.0758 |
HQY
Healthequity Inc
|
87.83 | 7.39B | 1.31B | 215.20M | 408.32M | 2.4627 |
HNGE
Hinge Health Inc
|
53.27 | 4.28B | 646.34M | -512.40M | 202.76M | -6.6871 |
Tempus Ai Inc Stock (TEM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Eingeleitet | Jefferies | Underperform |
| 2026-04-13 | Hochstufung | TD Cowen | Hold → Buy |
| 2026-02-19 | Eingeleitet | Mizuho | Outperform |
| 2026-02-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-10-21 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-10-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-09-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-21 | Eingeleitet | BTIG Research | Buy |
| 2025-02-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-02-05 | Fortgesetzt | TD Cowen | Buy |
| 2024-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-09 | Eingeleitet | Guggenheim | Buy |
| 2024-11-11 | Herabstufung | Stifel | Buy → Hold |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-08-12 | Eingeleitet | Piper Sandler | Neutral |
| 2024-07-09 | Eingeleitet | BofA Securities | Buy |
| 2024-07-09 | Eingeleitet | JP Morgan | Overweight |
| 2024-07-09 | Eingeleitet | Longbow | Buy |
| 2024-07-09 | Eingeleitet | Loop Capital | Buy |
| 2024-07-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-07-09 | Eingeleitet | Needham | Buy |
| 2024-07-09 | Eingeleitet | Stifel | Buy |
| 2024-07-09 | Eingeleitet | TD Cowen | Buy |
| 2024-07-09 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Tempus Ai Inc Aktie (TEM) Neueste Nachrichten
Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting - Business Wire
Wellington Shields Capital Management LLC Buys Shares of 23,594 Tempus AI, Inc. $TEM - MarketBeat
Handelsbanken Fonder AB Purchases Shares of 31,600 Tempus AI, Inc. $TEM - MarketBeat
Tempus AI, Inc. (TEM) Stock Analysis: A Balanced Look At Its 45% Potential Upside - DirectorsTalk Interviews
Tempus AI, Inc. Class A Common Stock (TEM) Live Share Price, Invest From India - INDmoney
Tempus AI (TEM) Launches ArteraAI Prostate Test, The First Externally Developed Digital Pathology Algorithm - Insider Monkey
Tempus AI Expands Cancer Platform With Launch of ArteraAI Prostate Test For Metastatic Patients - Stocktwits
Tempus AI, Inc. (TEM) and Bristol Myers Announce a Strategic Partnership - Insider Monkey
Tempus AI (NASDAQ: TEM) investors choose 3-year say-on-pay cycle - Stock Titan
Tempus AI Stock (TEM) Opinions on Fund Holdings and Trading Strategies - Quiver Quantitative
Tempus AI: Taking Advantage Of Investor Myopia (NASDAQ:TEM) - Seeking Alpha
Tempus releases digital test for prostate cancer prognosis - Crain's Chicago Business
TEM Stock Chart | TEMPUS AI INC-CL A (NASDAQ:TEM) - ChartMill
Tempus AI Insiders Sold Shares Worth Over $1.5M - TradingView
Tempus AI (TEM) Diagnostics CEO sells 1,580 shares for RSU tax withholding - Stock Titan
Tempus AI (TEM) CFO’s mandated share sale covers RSU tax obligations - Stock Titan
Tempus AI (TEM) legal chief’s non-discretionary tax sell-to-cover trade - Stock Titan
Tempus AI (TEM) CEO Lefkofsky sells 22,335 shares to cover RSU taxes - Stock Titan
Tempus AI (TEM) executive logs 13,550-share tax sell-to-cover transaction - Stock Titan
Tempus AI (TEM) CAO executes mandatory sell-to-cover for RSU taxes - Stock Titan
Tempus AI Launches AI Powered Prostate Cancer Risk Test - Moomoo
Tempus launches AI prostate cancer test on its platform - Investing.com UK
Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use - Yahoo Finance
1TEM.MI Stock Price, Quote & Chart | TEMPUS AI INC-CL A (BIT:1TEM) - ChartMill
TEM (NASDAQ: TEM) director reports sale of 2,902 shares for $171K - Stock Titan
James W. Rogers sells 21,498 shares at TEM (NASDAQ: TEM) - Stock Titan
[144] Tempus AI, Inc. SEC Filing - Stock Titan
TEM (NASDAQ: TEM) notice: insider plans to sell RSU-derived Class A shares - Stock Titan
TEM (NASDAQ: TEM) Rule 144 lists RSUs and two 10b5-1 sales by Andrew Polovin - Stock Titan
Eric Lefkofsky sells TEM (NASDAQ: TEM) Class A shares reported in Form 144 - Stock Titan
TEM (NASDAQ: TEM) affiliate seeks to sell 9,592 Class A shares for $566K - Stock Titan
Long term debt to total assets ratio of Tempus AI, Inc. Class A – HAM:F3M - TradingView
Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery - Benzinga
ETFs Investing in Tempus AI, Inc. Class A Stocks - TradingView
Price to sales ratio of Tempus AI, Inc. Class A – HAM:F3M - TradingView
Cash per share of Tempus AI, Inc. Class A – HAM:F3M - TradingView
Tempus AI, Inc. Class A Trade Ideas — HAM:F3M - TradingView
InvestingPro spotted Tempus AI’s 40% decline months in advance By Investing.com - Investing.com
Tempus AI Earnings Call Highlights Data-Driven Growth - TipRanks
TEM Technical Analysis | Trend, Signals & Chart Patterns | TEMPUS AI INC-CL A (NASDAQ:TEM) - ChartMill
4 Heavily Shorted AI Stocks to Watch Right Now - Schaeffer's Investment Research
Piper Sandler Maintains Tempus AI (TEM) Neutral Recommendation - MSN
US88023BAG8 Bond Analysis — Key Metrics - TradingView
AI in cardiology set to grow as Tempus projects $1.59B 2026 sales - Stock Titan
Assessing Tempus AI (TEM) Valuation After Recent Share Price Weakness - Yahoo Finance
Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts - Yahoo Finance
ARK Invest Increases AI and Genomic Holdings While Reducing Semi - GuruFocus
Tempus AI And BMS Deepen AI Drug Development Ties As Losses Persist - Yahoo Finance
How Beaten-Down Tempus AI Stock Offers a Lottery Ticket for Traders Here - Barchart
7 Healthcare AI Stocks Under $50 With Huge Upside Potential - 24/7 Wall St.
Cathie Wood’s weekly update: buys Cerebras, Tempus AI, sells AMD and TSM (ARKK:BATS) - Seeking Alpha
Finanzdaten der Tempus Ai Inc-Aktie (TEM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tempus Ai Inc-Aktie (TEM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Rogers James William | Chief Financial Officer |
May 19 '26 |
Sale |
44.07 |
10,853 |
478,292 |
126,395 |
| Polovin Andrew | EVP, Chief Legal Officer |
May 19 '26 |
Sale |
44.07 |
8,703 |
383,541 |
128,215 |
| LEFKOFSKY ERIC P | CEO and Chairman |
May 19 '26 |
Sale |
44.07 |
22,335 |
984,303 |
2,230,721 |
| Fukushima Ryan | CEO, Data |
May 19 '26 |
Sale |
44.07 |
13,550 |
597,148 |
603,558 |
| Bartolucci Ryan M | Chief Accounting Officer |
May 19 '26 |
Sale |
44.07 |
4,116 |
181,392 |
74,041 |
1.08%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):